Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853909 | 0.83 | S1PR1 (0.78) | S1PR1S1PR3 | |
| SCHEMBL1858171 | 0.82 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL1857592 | 0.81 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL1860290 | 0.81 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL1853479 | 0.80 | S1PR1 (0.67) | S1PR1S1PR3 | |
| SCHEMBL1857959 | 0.80 | S1PR1 (0.67) | S1PR1S1PR3 | |
| SCHEMBL1864745 | 0.80 | S1PR1 (0.80) | S1PR1S1PR3 | |
| SCHEMBL1856225 | 0.80 | S1PR1 (0.81) | S1PR1S1PR3 | |
| SCHEMBL2747677 | 0.79 | S1PR1 (0.42) | S1PR1S1PR3 | |
| SCHEMBL1854600 | 0.79 | S1PR1 (0.64) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979345-B1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-04 | — | — | EP | claimed |
| US-20090005421-A1 | Novel Pyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | claimed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | claimed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | claimed |
| US-8697732-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-02 | — | — | US | disclosed |
| US-8178562-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-05-15 | — | — | US | disclosed |
| EP-1979345-B1 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-20090005421-A1 | Novel Pyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1979345-A2 | NOVEL PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007086001-A2 | NOVEL PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005421-A1 | Novel Pyridine Derivatives | NFATC1, TPMT, CD47 | S1PR1 1245/4885S1PR3 1086/4885 |
| US-20120195930-A1 | NOVEL PYRIDINE DERIVATIVES | NFATC1, TPMT, CD47 | S1PR1 1245/4885S1PR3 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.